Business
Moleculin Announces Publication of Data Supporting Development of Non-Cardiotoxic Anthracycline for the Treatment of Cancer in Peer-Reviewed European Journal of Cancer
Annamycin appears to be a highly promising non-cardiotoxic, potent TOPO-II inhibitor able to overcome MDR-1 that, due to its unique organotropism, is also
About this update from Moleculin Biotech, Inc.
[{"type":"text","content":"Annamycin appears to be a highly promising non-cardiotoxic, potent TOPO-II inhibitor able to overcome MDR-1 that, due to its unique organotropism, is also able to target hard-to-treat metastasis\nIn an independent expert cardiology review of 42 subjects evaluated as of the date of the review, Annamycin has demonstrated no evidence of cardiotoxicity \nAnnamycin is currently being evaluated in clinical studies for the treatment of soft tissue sarcoma (STS) metastatic to the lungs and acute myelogenous leukemia (AML)\nHOUSTON, March 9, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced the publication of data evaluating Annamycin's performance as an anthracycline designed to avoid the cardiotoxicity typically associated with currently prescribed anthracyclines. The manuscript titled, \"Anthracycline-induced cardiotoxicity – are we about to clear this hurdle?1,\" was published in the peer-reviewed European Journal of Cancer.\n\n \n \n \n \n \n \n\n \nThe published manuscript discusses clinically evaluated doxorubicin analogs that were developed as potentially non-cardiotoxic anticancer agents and includes Annamycin. The anthracycline family of drugs (i.e., doxorubicin, daunorubicin, epirubicin, idarubicin) has significantly contributed to marked improvements of overall survival (OS) during the last few decades and represents one of the most potent cytostatic drugs for cancer treatment across various histologies (5-year overall survival of 80%).\n\"Despite the major impact of anthracyclines on overall survival in the treatment of a wide spectrum of solid tumors and hematologic malignancies, the development of life-threatening cardiotoxicity still remains a huge challenge for physicians treating cancer patients. Annamycin has consistently demonstrated little to no cardiotoxicity to date and we continue to be highly encouraged by its potential. The discussion throughout this manuscript further demonstrates that the development of non-cardiotoxic anthracyclines is not only feasible, but an elegant and much-needed approach to eliminate this potentially life-threatening adverse event in patients with cancer,\" commented Walter Klemp, Chairman and CEO of Moleculi...